Noticias de Genzyme

December 9, 2009	Genzyme Laboratory Recognized for Quality
December 8, 2009	Robert J. Bertolini Elected to Genzyme’s Board of Directors
December 8, 2009	Genzyme’s Mozobil Shows Promise in Chemosensitization
December 7, 2009	Genzyme Phase 3 Trial of Campath/Fludara Combination Shows Potential Benefit in Second-Line CLL
December 3, 2009	Genzyme to Reopen Enrollment in Alglucosidase Alfa Temporary Access Program
December 1, 2009	Genzyme Begins Shipping Newly Produced Cerezyme from Allston Plant
November 18, 2009	Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
November 17, 2009	Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA
November 16, 2009	Genzyme Receives Complete Response Letter on Lumizyme Application
November 13, 2009	Genzyme Issues Letters to U.S. Healthcare Providers
October 21, 2009	Genzyme Reports Third-Quarter Financial Results
October 20, 2009	First Patient Enrolled in Phase 3 Trials of Genzyme Oral Capsule for Gaucher Disease
October 14, 2009	Scientists Name Genzyme a Top Employer
October 6, 2009	Genzyme Receives FDA Complete Response Letter for Clolar
October 2, 2009	Genzyme Named to Dow Jones Sustainability World and North American Indexes
September 24, 2009	Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
September 23, 2009	Genzyme Provides Update on Cerezyme and Fabrazyme Supply
September 11, 2009	Genzyme’s Alemtuzumab for Multiple Sclerosis Shows Durable Treatment Benefit in Review of Four-Year Phase 2 Trial Data
September 01, 2009	FDA Advisory Committee Recommends Randomized Trial to Support Proposed Indication for Clolar in Adult AML
August 28, 2009	FDA Advisory Committee to Discuss Genzyme’s Clolar for Adult AML on Sept. 1
August 10, 2009	Genzyme Provides Update on Cerezyme Supply and 2009 Financial Information
August 5, 2009	European Commission Approves Genzyme’s Mozobil
July 31, 2009	Genzyme Provides Update on Allston Landing Plant
July 22, 2009	Genzyme Delivers Solid Second-Quarter Financial Results
June 25, 2009	Genzyme Reports Progress Related to Allston Plant
June 16, 2009	Genzyme Temporarily Interrupts Production at Allston Plant
June 12, 2009	Genzyme Receives European Approval of Renvela for Patients with Chronic Kidney Disease
June 2, 2009	Genzyme Completes Transaction with Bayer HealthCare
May 29, 2009	Genzyme Receives Positive Opinion for European Approval of Mozobil
May 21, 2009	Genzyme Submits All Information Requested by FDA for Lumizyme
May 20, 2009	Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
May 6, 2009	Genzyme Provides Outlook for Long-Term Growth at its Analyst Day Meeting
April 22, 2009	Genzyme Reports Solid Financial Results for the First Quarter of 2009
March 31, 2009	Genzyme and Bayer HealthCare Enter New Strategic Agreement
March 19, 2009	Genzyme Receives Positive Opinion for European Approval of Renvela for Patients with Kidney Disease
March 2, 2009	Genzyme Receives Complete Response Letter from FDA on Lumizyme Application
February 26, 2009	European Authorities Approve Larger-Scale Production of Genzyme’s Myozyme
February 26, 2009	FDA Approves Genzyme’s Synvisc-One for Osteoarthritis of the Knee
February 19, 2009	Genzyme Receives Positive Opinion on Myozyme from CHMP
October 15, 2008	Genzyme Begins Enrollment in Post-Marketing Study to Evaluate Use of Low Dose Fabrazyme Treatment for Fabry Disease
September 23, 2008	Mozobil Receives Priority Review with FDA Action Expected by Year End; Synvisc-ONE FDA Action also Expected by Year End

Términos y Condiciones de Uso | Política de Privacidad | © 2010 Genzyme Corporation. Todos los Derechos Reservados.